clinical trial · NCT04145349
CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company·phase2·completed·n = 30
Desmoplastic Small Round Cell TumorRamucirumabCyclophosphamideVinorelbine
brief summary
This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.
started
Jan 22, 2020
primary completion
Jun 14, 2024
completion
Jan 23, 2026
last updated
May 11, 2026
official title
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol